The abstract is read at the publisher; the summary is JClub's.
A single liver-sparing MyoAAV4E-off AAV delivering SlugABE8e efficiently restores dystrophin expression in juvenile humanized DMD mice while reducing liver editing.
- Why it matters: DMD mutations often require exon-skipping correction, but conventional AAV delivery is limited by packaging constraints and toxicity at high doses. Liver off-target editing also raises safety concerns for systemic therapy.
- What they did: The study used an all-in-one AAV vector carrying the compact adenine base editor SlugABE8e and a single-guide RNA, delivered systemically with muscle-tropic MyoAAV4A in juvenile humanized DMD mice. It also tested a liver-detargeted MyoAAV4E-off capsid and a high-fidelity editor SlugHF-ABE8e(V106W) for comparable on- and off-target editing.
- The result: MyoAAV4A delivery restored dystrophin expression in heart and skeletal muscles, lowered serum creatine kinase activity, and reduced muscle pathology. MyoAAV4E-off eliminated viral entry and editing in the liver, supporting a safer AAV strategy to mitigate DMD progression.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.